Device longevity matters to all – patients, physicians and hospitals. Patients are receiving implantable cardioverter
defibrillators (ICDs) and cardiac resynchronisation therapy defibrillators (CRT-Ds) earlier and are living longer – over 40%
of ICD patients were still living after 10 years.1
Registry data show that about 70% of ICD patients need at least one replacement due to the end of the device’s
In addition, lead failure is becoming an increasingly prevalent problem.3 Every time a patient has replacement surgery,
there are risks as well as associated costs for the healthcare system.
Device longevity can improve quality of life, reduce healthcare costs and improve value for money.
Keep reading to find out more about device longevity today.
- Hauser RG. The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. J Am Coll Cardiol 2005; 45:2022-2025.
- Gould PA et al. Outcome of advisory implantable cardioverter-defibrillator replacement: One-year follow-up. Heart Rhythm 2008;5;1675-1681.
- Groarke JD et al. Cost implications of defibrillator lead failures, Europace, 2012; 14; 8: 1156-1160.